INTRODUCTION
The autoimmune lymphoproliferative syndrome (ALPS) is characterized by childhood onset chronic lymphadenopathy, splenomegaly, multilineage cytopenias secondary to sequestration and autoimmune destruction, and an increased risk of B-cell lymphoma 1 .
Laboratory findings include polyclonal hypergammaglobulinemia and expansion of a unique population of circulating TCRαβ + B220 + CD4 -CD8 -T (αβ + -DNT) lymphocytes 2, 3 .
The majority of ALPS patients harbor heterozygous autosomal dominant germline mutations in FAS, with somatic FAS mutations representing the second most common genetic etiology 4, 5, 6, 7 . Germline mutations in the genes encoding FAS ligand and caspase 10 have been identified in a small minority of patients [8] [9] [10] [11] [12] [13] . In our cohort, about one-third of the ALPS patients have an undetermined genetic basis. In addition, there is a group of genetically undetermined ALPS-like patients without αβ + -DNT cell elevation.
We recently reported one individual among these latter patients with a syndrome of lymphoproliferation, autoimmunity and minimally increased αβ + -DNT cells caused by a somatic mutation in the NRAS gene resulting in defective lymphocyte apoptosis 13 . Here
Somatic KRAS mutations causing an ALPS-like syndrome 79 we demonstrate that somatic mutations in the homologous KRAS gene can also be associated with a syndrome consisting of autoimmune phenomena and dysregulated leukocyte homeostasis, with normal αβ + -DNT cells. The activating KRAS mutation, like the previously described NRAS mutation, impaired intrinsic T cell apoptosis through the suppression of the pro-apoptotic protein BIM and facilitated cellular proliferation by repression of p27 kip1 .
METHODS

Cells and treatments
All patients were studied at the National Institutes of Health under IRB approved protocols (93-I-0063 and 95-I-0066). DNA sequencing, apoptosis assays, immunoblotting and active RAS pull down were performed as previously described 13 .
Plasmids and transfection
The plasmids pCEFL-KZ-AU5-KRAS-wt and pCEFL-KZ-AU5-KRAS-V12 were kindly provided by Silvio Gutkind (NIDCR, NIH, Bethesda, MD). AU5-tagged KRAS G13C
plasmid was constructed by site-directed mutagenesis using the QuickChange kit (Fig. 1C) . KRAS G12D is already described to produce a gain-of-function 14 .
RESULTS AND DISCUSSION
Somatic gain-of-function KRAS mutation in two patients with ALPS-like symptoms
Clinical history and laboratory findings
Patient 1
This Caucasian female patient had a history of lymphadenopathy and splenomegaly first noted at 4 years of age at the time of a tonsillectomy and adenoidectomy for recurrent upper respiratory tract infections. Splenomegaly, autoimmune hemolytic anemia and thrombocytopenia (Evan's syndrome) were diagnosed at follow-up. She was evaluated at the NIH at 9 years of age and found to have positive serology for several autoantibodies and polyclonal hypergammaglobulinemia as well as persistent splenomegaly and lymphadenopathy (Table 1) . Flow cytometry did not reveal the hallmark elevation of αβ + -DNTs seen in ALPS, but documented B cell lymphocytosis and monocytosis (Table   1 ). Lymph node biopsy demonstrated plasmacytosis but no paracortical infiltration by 
Patient 2
This patient is a Caucasian female of Italian ancestry who was first noted to have splenomegaly with neutropenia, monocytosis, reticulocytosis, thrombocytopenia, and hyperuricemia when evaluated for a routine respiratory tract infection with facial rash at 5 years of age. Serologies were positive for Parvovirus B19 and EBV and the findings were attributed to acute viral infection, with hematologic parameters returning to near normal levels five months later. The patient remained well with the exception of periodic, painful, erythematous bilateral swelling of the ankles progressing to ecchymosis over a short period, which occurred once to twice yearly and was associated with swimming and beach activities. Following an abrupt increase in the frequency and severity of these symptoms at 7 years of age, the patient was referred for further evaluation and found to have pancytopenia, massive splenomegaly with bulky intra-abdominal and inguinal lymphadenopathy, marked hypergammaglobulinemia and anticardiolipin and anti-ß2-glycoprotein-I antibodies. Bone marrow examination showed only a hyperreactive state.
Hematological malignancy and lysosomal storage diseases were excluded. A diagnosis of Evan's syndrome was considered based upon presence of anti-neutrophil and anti-platelet antibodies. She had normal cognitive and motor development throughout these episodes.
Weight and height were normal at birth, decreasing progressively to ~3%ile currently.
She continued to the present with rash of the lower extremities presumed to represent a vasculopathy secondary to antiphospholipid syndrome, but is otherwise well. Positive (23) Positive (20) 
KRAS mutation impaired lymphocyte apoptosis and increased proliferation
We evaluated lymphocyte apoptosis and proliferation in samples from Patient 1 and found the KRAS G13C mutation did not impair FAS mediated apoptosis but induced resistance to apoptosis triggered by IL-2 withdrawal of activated T lymphocytes (Fig. 3A,   B ). As BIM, a pro-apoptotic protein of the BCL-2 family, is the main mediator of this form of apoptosis 15 , we checked the patient's cells and found markedly reduced BIM levels compared to normal controls or ALPS-FAS patients (Fig. 3C) . These findings are reminiscent of our previous work describing a patient with a mutation in NRAS 13 . We speculate that low BIM levels underlie the accumulation of B-cells and monocytes in these patients, given the critical role for this protein in leukocyte homeostasis in murine models 15 .
Apoptosis resistance in Patient 1 was at least partially mediated by downstream ERK and PI3K hyperactivation, as the addition of MEK1 (PD98059, 20 µM) or PI3K (LY294002, 10 µM) inhibitors almost completely abrogated the apoptotic defect in vitro (Fig. 3D ) 16 . Myeloid cells from patients with somatic KRAS mutations associated with juvenile myelomonocytic leukemia, unlike normal myeloid cells, expand in the presence of low GM-CSF concentrations 17 . We hypothesized that a similar phenomenon could be present with the patient's cells and cultured activated primary lymphocytes under limiting IL-2 concentrations and demonstrated increased proliferation compared to controls (Fig.   3E ). This was linked to low levels of the cell cycle inhibitor protein p27 kip1 in primary cells and transfected cell lines, as previously described for cancer cells (Fig. 3F ) 18, 19 .
As any missense mutation at certain RAS codons including 12,13, and 61 are known prevent interactions with GTPase-activating proteins and thus greatly decrease GTP hydrolysis, resulting in constitutively active RAS 20 , it is reasonable to speculate that the KRAS G12D mutation in Patient 2 also impairs apoptosis and proliferation.
Moreover, the G12V control demonstrated repressed p27kip1 levels. 
The spectrum of clinical manifestations associated with somatic RAS mutations
KRAS is a member of the p21 small GTPase family of proteins that also includes HRAS and NRAS. Germline RAS mutations are associated with specific developmental disorders including Noonan, Costello and cardio-facio-cutaneous syndromes 21 . Somatic RAS mutations are seen in more than 30% of all human cancers 16 . In the hematopoietic system, somatic KRAS and NRAS mutations are commonly observed in aggressive tumors such as multiple myeloma or juvenile myelomonocytic leukemia (JMML) 22 .
This report and our previous work 13 suggest that activating somatic mutations in NRAS or KRAS can be associated with a non-malignant hematological syndrome, which we refer to as RAS-associated autoimmune leukoproliferative disease (RALD) 23 . The factors determining which patients with somatic RAS mutations develop hematological malignancy versus RALD are unknown, but a previous report also demonstrated that patients with somatic NRAS or KRAS mutations could follow a more benign clinical course 24 .
The clinical entity described here seems distinct from ALPS in several respects:
the characteristic αβ + -DNT cells are present at normal levels or only marginally elevated in the peripheral blood, and absent in lymph nodes; there is no defect in the FAS pathway of apoptosis; biomarkers typically associated with ALPS such us IL-10 and sFASL 25, 26 are normal; and monocytosis, reminiscent of JMML, was seen in all the patients evaluated to date (Table 2) .
We suggest that RALD should be considered in the differential diagnosis of patients with autoimmune cytopenias, monocytosis and lymphoid organ expansion. These patients may in the future benefit from therapies directed at blocking ERK and/or RAS that are under development as cancer therapeutics. 
